Generic Name: cycloSPORINE
Brand Names:
Sandimmune, Gengraf, Sangcya, Neoral
Supervising Clinician and Medical Resources
- Only clinicians experienced in management of systemic immunosuppressive therapy for the indicated disease and/or management of organ transplant patients should prescribe cyclosporine.
- Patients should be managed in facilities with adequate laboratory and supportive medical resources; the clinician responsible for maintenance therapy should have complete information for patient follow-up.
Effects of Immunosuppression
- Immunosuppression may result in increased susceptibility to infection and possible development of lymphoma or other neoplasms. (See Lymphomas and Other Malignancies under Cautions.)
- Manufacturer cautions that conventional (nonmodified) oral formulations and the concentrate for injection should be administered with corticosteroids but not with other immunosuppressive agents in organ transplant recipients. Manufacturers state that modified oral formulations of cyclosporine (Neoral® and Gengraf®) may be administered with oral immunosuppressive agents in transplant patients, although the degree of immunosuppression produced may result in increased susceptibility to infection and possible development of lymphoma and other neoplasms.
Bioequivalency of Formulations
- Conventional (nonmodified) oral formulations (Sandimmune® liquid-filled capsules and solution) have decreased bioavailability compared with modified oral formulations (Neoral® and Gengraf® liquid-filled capsules and solution). Conventional (nonmodified) and modified formulations are not bioequivalent and cannot be used interchangeably without physician supervision. (See Conversion from Conventional Oral Formulations [Sandimmune®] to Modified Oral Formulations [Gengraf®, Neoral®] under Dosage and Administration.)
- Absorption of cyclosporine during chronic administration of Sandimmune® capsules and oral solution may be erratic. Patients, especially liver transplant recipients, receiving these formulations over a period of time should be monitored at repeated intervals for blood cyclosporine concentrations and possible organ rejection due to low absorption of cyclosporine.
- For a given trough concentration, cyclosporine exposure will be greater with Neoral® or Gengraf® preparations than with Sandimmune® preparations. Exercise particular caution if a patient is receiving exceptionally high doses of Sandimmune® and is converted to Gengraf® or Neoral®. (See Conversion from Conventional Oral Formulations [Sandimmune®] to Modified Oral Formulations [Gengraf®, Neoral®] under Dosage and Administration.)
- Patients receiving Gengraf® or Neoral® liquid-filled capsules or oral solution for organ transplant or in the management of rheumatoid arthritis should also have blood cyclosporine concentrations monitored to avoid toxicity due to high concentrations. (See Monitoring of Cyclosporine Concentrations under Cautions.)
Psoriasis Patients
- Previous therapy with psoralen and UVA light (PUVA) and, to a lesser extent, methotrexate, other immunosuppressive agents, UVB, coal tar, or radiation therapy may increase risk of skin malignancies in patients receiving cyclosporine.
- Recommended dosages can cause hypertension and nephrotoxicity; risk increases with dose and duration of therapy. Monitor renal function (see General: Psoriasis, under Dosage and Administration).
 | E0933 100 mg
bottle, 30 each Cyclosporine, Modified 100mg, Oral capsule, yellow, translucent, oblong-shaped, side 1:E0933 |
 | PA20 100 mg
box, 5 unit dose blister packs, 6 each Cyclosporine, Modified 100mg, Oral capsule, white, oblong-shaped, side 1:PA20 |
 | E0932 25 mg
box, 3 single item blister cards, 10 each Cyclosporine, Modified 25mg, Oral capsule, yellow, translucent, oval-shaped, side 1:E0932 |
 | LOGO 50 mg 50 mg
box, 30 unit dose strips, 1 each Cyclosporine, Modified 50mg, Oral capsule, yellow, oblong-shaped, side 1:LOGO 50 mg |
The Healthline Site, its content, such as text, graphics, images, search results, HealthMaps, Trust Marks,
and other material contained on the Healthline Site ("Content"), its services, and any information or material
posted on the Healthline Site by third parties are provided for informational purposes only. None of the
foregoing is a substitute for professional medical advice, examination, diagnosis, or treatment. Always seek
the advice of a physician or other qualified healthcare provider with any questions you may have regarding a
medical condition. Never disregard professional medical advice or delay in seeking it because of something you
have read on the Healthline Site. If you think you may have a medical emergency, call your doctor or 911 immediately.
Please read the
Terms of Service
for more information regarding use of the Healthline Site.
